Technical Analysis for AMAG - AMAG Pharmaceuticals, Inc.

Grade Last Price % Change Price Change
grade F 15.93 -0.50% -0.08
AMAG closed down 0.5 percent on Wednesday, February 20, 2019, on 53 percent of normal volume. It ran into resistance at its 50 day moving average.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Down Down Flat
See historical AMAG trend table...

Date Alert Name Type % Chg
Feb 20 20 DMA Resistance Bearish 0.00%
Feb 20 50 DMA Resistance Bearish 0.00%
Feb 20 Spinning Top Other 0.00%
Feb 19 Fell Below 20 DMA Bearish -0.50%
Feb 19 Fell Below 50 DMA Bearish -0.50%
Feb 19 Non-ADX 1,2,3,4 Bearish Bearish Swing Setup -0.50%
Feb 19 Outside Day Range Expansion -0.50%
Feb 15 NR7 Range Contraction -4.67%
Feb 15 Up 3 Days in a Row Strength -4.67%
Feb 15 Up 4 Days in a Row Strength -4.67%

Older signals for AMAG ...

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Profile
AMAG Pharmaceuticals, Inc., a biopharmaceutical company, engages the development and commercialization of a therapeutic iron compound to treat iron deficiency anemia (IDA). The company's principal product includes Feraheme (ferumoxytol) injection for intravenous (IV) use, which was approved for marketing in the United States in June 2009 by the U.S. Food and Drug Administration, for use as an IV iron replacement therapy for the treatment of IDA in adult patients with chronic kidney disease (CKD). The company also markets Feraheme in Canada, the European Union, and Switzerland. In addition, its development projects comprise Feraheme for patients with IDA regardless of the underlying cause, which has completed Phase III clinical program. The company sells Feraheme primarily to authorized wholesalers and specialty distributors. AMAG Pharmaceuticals, Inc. has a license, development, and commercialization agreement with Takeda Pharmaceutical Company Limited to develop and commercialize Feraheme/Rienso as a therapeutic agent in Europe, certain Asia-Pacific countries, the Commonwealth of Independent States, Canada, India, and Turkey; and collaboration and exclusive license agreement with 3SBio for the development and commercialization of Feraheme as a therapeutic agent in China for an initial indication for the treatment of IDA in patients with CKD and an option to expand into additional therapeutic indications. The company was founded in 1981 and is headquartered in Lexington, Massachusetts.
Health Biopharmaceutical Medication Chronic Kidney Disease U.S. Food And Drug Administration European Union Commonwealth Day Commonwealth Of Independent States
Is AMAG a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 3 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 26.1
52 Week Low 14.35
Average Volume 581,904
200-Day Moving Average 20.5198
50-Day Moving Average 16.088
20-Day Moving Average 15.9655
10-Day Moving Average 15.873
Average True Range 0.7279
ADX 12.14
+DI 21.8212
-DI 20.2599
Chandelier Exit (Long, 3 ATRs ) 15.2063
Chandelier Exit (Short, 3 ATRs ) 16.8837
Upper Bollinger Band 16.9734
Lower Bollinger Band 14.9576
Percent B (%b) 0.48
BandWidth 12.625975
MACD Line -0.0551
MACD Signal Line -0.1128
MACD Histogram 0.0577
Fundamentals Value
Market Cap 562.14 Million
Num Shares 35.3 Million
EPS -1.30
Price-to-Earnings (P/E) Ratio -12.25
Price-to-Sales 0.90
Price-to-Book 0.57
PEG Ratio 0.30
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 16.55
Resistance 3 (R3) 16.57 16.38 16.44
Resistance 2 (R2) 16.38 16.23 16.37 16.41
Resistance 1 (R1) 16.16 16.13 16.07 16.14 16.37
Pivot Point 15.97 15.97 15.93 15.96 15.97
Support 1 (S1) 15.75 15.82 15.66 15.73 15.49
Support 2 (S2) 15.56 15.72 15.55 15.45
Support 3 (S3) 15.34 15.56 15.42
Support 4 (S4) 15.32